1stOncology™: Cancer Intelligence Service – Page 8797 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

CohBar to Present at the BIO 2021 Digital Conference

On June 10, 2021 CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, reported its Chief Executive Officer Dr. Joseph Sarret will present a corporate overview at the BIO 2021 Digital Conference, to be held on June 14 – 18, 2021 (Press release, CohBar, JUN 10, 2021, View Source [SID1234583833]). This presentation will be available on demand for registered attendees.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

BIO is the world’s largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.

Onconova Therapeutics Announces Participation In A.G.P.’S Upcoming Virtual Summer Healthcare Symposium

On June 10, 2021 Onconova Therapeutics, Inc. (NASDAQ: ONTX) ("Onconova"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, reported that members of the Company’s management team will participate in A.G.P.’s Virtual Summer Healthcare Symposium on Thursday, June 17, 2021 (Press release, Onconova, JUN 10, 2021, View Source [SID1234583832]).

The event will consist of 1-on-1 virtual investor meetings. Investors participating in the virtual conference who are interested in meeting with members of Onconova’s management team should contact their A.G.P. representative.

Kura Oncology to Participate in JMP Securities Life Sciences Conference

On June 10, 2021 Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, reported its participation in the JMP Securities Life Sciences Conference (Press release, Kura Oncology, JUN 10, 2021, View Source [SID1234583831]). Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to present in a virtual fireside chat at 3:00 p.m. ET / 12:00 p.m. PT on Thursday, June 17, 2021.

A live audio webcast of the presentation will be available in the Investors section of Kura’s website at www.kuraoncology.com, with a replay available shortly after the live event.

Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise

On June 10, 2021 Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) reported that the Company’s share capital has been increased by nominally DKK 804,440 as a consequence of employees’ exercise of warrants (Press release, Bavarian Nordic, JUN 10, 2021, View Source [SID1234583828]).

The capital increase was effected without any pre-emption rights for the existing shareholders of the Company or others. A total of 80,444 new shares were subscribed for in cash at DKK 205.80 per share of nominally DKK 10. The total proceeds to Bavarian Nordic A/S from the capital increase amounts to DKK 16.6 million.

The new shares, which will rank pari passu in all respects with existing Bavarian Nordic shares, will be admitted to trading and official listing on Nasdaq Copenhagen as soon as possible.

After the capital increase, the total nominal value of Bavarian Nordic A/S’ share capital is DKK 638,172,480, which is made up of 63,817,248 shares of a nominal value of DKK 10 each, corresponding to 63,817,248 votes.

The revised Articles of Association will be published separately and will subsequently be available on the Company’s website.

The content of this announcement does not affect the Company’s expectations for the financial results for 2021.

HOOKIPA Pharma to Participate in Upcoming Investor Conferences in June

On June 10, 2021 HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, reported that HOOKIPA’s management team will participate and present at the following upcoming virtual investor conferences (Press release, Hookipa Biotech, JUN 10, 2021, View Source [SID1234583827]):

SVB Leerink CybeRx Series: Vaccine Forum, June 21 – 22, 2021

JMP Securities Life Sciences Conference, June 16 – 17, 2021
Fireside Chat: June 17, 10:00am ET
The live audio webcast of the fireside chat will be available within the Investors & Media section of HOOKIPA’s website at View Source An archived replay will be accessible for 30 days following the event.